5
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Preclinical Studies and Optimization of Specific Tumor Delivery for 741F8 sFv, an Anti-c-erbB-2 Single-Chain Species

, , , , , , , , , , , , , , & show all
Pages 75-91 | Published online: 20 Oct 2008
 

Abstract

Single-chain Fv fragments (sFv) that bind tumor-associated antigens exhibit highly specific tumor targeting characteristics, based on studies of intravenous sFv administration to immunodeficient mice bearing human tumor xenografts. These features suggest that sFv may be used as targeting vehicles for diverse agents such as radionuclides, toxins, chemotherapeutic agents, or genes. However, the quantitative tumor retention of sFv molecules is lowered by their fast clearance and rapid dissociation from antigen. We have found that the retention of tumor-specific 74IF8 sFv in tumor is an antigen-specific event and not the result of extravascular pooling. We also have produced divalent 741F8 (sFv')2 species and have examined their pharmacokinetics and biodistribution properties in relevant tumor-bearing scid mice. Finally, we have employed a number of strategies to optimize the tumor-specific retention of radiolabeled sFv molecules; escalations in administered doses, repetitive intravenous bolus administrations, subcutaneous continuous infusions and the use of an alternate labeling system.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.